Clinical Trial Update: Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) [Phase 2]

View source ↗

Summary

Phase 2 BRAVIO trial evaluated transitioning from intravenous to oral varespladib as a broad-spectrum antidote for snakebite envenomation; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Snake Envenomation
• Snakebite

Drugs mentioned

• Varespladib (varespladib)

Snippet

Sponsor: Ophirex, Inc. | Conditions: Snakebite, Envenoming, Snake | Phase 2 | Status: COMPLETED